OXiGENE Offers Results from Phase 2 Study of CA4P in Recurrent Ovarian Cancer: Study Met Primary Endpoint of Improvement
May 24, 2016 at 06:34 AM EDT
OXiGENE, Inc. (Nasdaq: OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan ...
